---
title: "iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint ventur"
description: "iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint venture in the U.S. iX will own 75 percent of the venture while Orion takes 25 percent and covers the capi"
type: "topic"
locale: "en"
url: "https://longbridge.com/en/topics/100000000473073.md"
published_at: "2026-02-16T12:20:07.000Z"
author: "[Old one](https://longbridge.com/en/profiles/26231229)"
---

# iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint ventur

iX Biopharma has announced a non-binding term sheet with Orion Specialty Labs to form a joint venture in the U.S. iX will own 75 percent of the venture while Orion takes 25 percent and covers the capital costs. The goal is to use Orion’s existing FDA-licensed facilities to bring iX’s WaferiX technology to market faster, with pilot production aimed for the second half of 2026. The deal is not yet final, and there’s no expected immediate financial impact for iX.���������

### Related Stocks

- [42C.SG - IX Biopharma](https://longbridge.com/en/quote/42C.SG.md)

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
